Abstract #4874

A Novel Iron-oxide-based T1 Contrast Agent outperforms Gd-DOTA for Magnetic Resonance Lymphography

Yeon Ji Chae¹, Mi-hyun Kim^2,3, Chul-Woong Woo⁴, Sang-Tae Kim⁴, Do-Wan Lee⁵, Hwon Heo¹, Monica Young Choi⁴, Yoonseok Choi⁶, Kyung Won Kim^1,4, and Dong-Cheol Woo^1,4

¹Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, ²Department of Radiation Science & Technology, Jeonbuk National University, Jeonbuk, Korea, Republic of, ³Trial Informatics. Inc, Seoul, Korea, Republic of, ⁴Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Republic of, ⁵Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, ⁶Medical Research Institute, Gangneung Asan Hospital, Gangneung-si, Gangwon-do, Korea, Republic of

Synopsis

Keywords: Contrast Agent, Contrast Agent, Magnetic resonance lymphography, Iron-oxide-based T1 contrast agentThe novel iron-oxide-based T1 contrast agent may be an optimal contrast agent for MR lymphangiography, because it enhances the lymphatics only without venous contamination for more than 1 hour. It can overcome the limitations of gadolinium-based contrast agents such as venous contamination and rapid washout.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.